

Medical Policy

Emend® (fosaprepitant dimeglumine)	
MEDICAL POLICY NUMBER	MED_Clin_Ops-113
CURRENT VERSION EFFECTIVE DATE	01/01/2024
APPLICABLE PRODUCT AND MARKET	Individual Family Plan: ALL Small Group: ALL Medicare Advantage: ALL

Brand New Day/Central Health Medicare Plan develops policies and makes coverage determinations using credible scientific evidence including but not limited to MCG™ Health Guidelines, the ASAM Criteria™, and other third party sources, such as peer-reviewed medical literature generally recognized by the relevant medical community, physician specialty society recommendations, and expert opinion as relevant to supplement those sources. Brand New Day/Central Health Medicare Plan Medical Policies, MCG™ Guidelines, and the ASAM Criteria™ are not intended to be used without the independent clinical judgment of a qualified health care provider considering the individual circumstances of each member's case. The treating health care providers are solely responsible for diagnosis, treatment, and medical advice. Members may contact Brand New Day/Central Health Medicare Plan Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Brand New Day/ Central Health Medicare Plan policy may contact the Health Plan. Brand New Day/Central Health Medicare Plan policies and practices are compliant with federal and state requirements, including mental health parity laws.

If there is a difference between this policy and the member specific plan document, the member benefit plan document will govern. For Medicare Advantage members, Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), govern. Refer to the CMS website at <http://www.cms.gov> for additional information.

Brand New Day/Central Health Medicare Plan medical policies address technology assessment of new and emerging treatments, devices, drugs, etc. They are developed to assist in administering plan benefits and do not constitute an offer of coverage nor medical advice. Brand New Day/Central Health Medicare Plan medical policies contain only a partial, general description of plan or program benefits and do not constitute a contract. Brand New Day/Central Health Medicare Plan does not provide health care services and, therefore, cannot guarantee any results or outcomes. Treating providers are solely responsible for medical advice and treatment of members. Our medical policies are updated based on changes in the evidence and healthcare coding and therefore are subject to change without notice. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). MCG™ and Care Guidelines® are trademarks of MCG Health, LLC (MCG).

PURPOSE

The purpose of this policy is to establish the clinical review criteria that support the determination of medical necessity for Emend® (fosaprepitant dimeglumine) therapy.

POLICY

Prior Authorization and Medical Review is required.

Coverage for Emend will be provided for six months and may be renewed.

- Max Units (per dose and over time): 150 billable units per 7 days

Medical Policy

Initial

- A. Patient is 6 months of age or older; **AND**
- B. Patient is not taking pimozone concurrently; **AND**

Prevention of Chemotherapy induced Nausea and vomiting (CINV)

- A. Patient is receiving highly* and/or moderately** emetogenic chemotherapy; **AND**
- B. Emend will be used in combination with a 5-HT3 antagonist such as ondansetron, granisetron, palonosetron, etc.; **AND**
- C. Emend will be used in combination with a corticosteroid such as dexamethasone.

*Highly Emetogenic Chemotherapy (HEC)

Carboplatin
Carmustine
Cisplatin
Cyclophosphamide
Dacarbazine
Doxorubicin
Epirubicin
Methotrexate
Streptozocin
Melphalan

Regimens: FOLFOX, FOLFIRI, FOLFIRINOX/FOLFOXIRI, AC (any anthracycline + cyclophosphamide)

*The following can be considered HEC in certain patients:

Dactinomycin
Daunorubicin
Irinotecan
Oxaliplatin
Methotrexate $\geq 250\text{mg/m}^2$
Trabectedin
Idarubicin

**Moderately Emetogenic Chemotherapy (MEC)

Aldesleukin $>12\text{-}15$ million IU/m²
Amifostine $>300\text{mg/m}^2$
Azacitidine
Bendamustine
Busulfan
Clofarabine
Cytarabine $>200\text{mg/m}^2$
Daunorubicin Liposomal
Cytarabine Liposomal
Dinutuximab
Fam-trastuzumab deruxtecan
Irinotecan Liposomal
Lurbinectedin
Temozolomide

Medical Policy

Renewal

- A. Patient continues to meet initial criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc.; **AND**
- B. Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: severe hypersensitivity reactions, severe infusion site reactions, etc.; **AND**
- C. Patient has experienced disease response.

LIMITATIONS/EXCLUSIONS

1. Any indication other than those listed above due to insufficient evidence of therapeutic value

DEFINITIONS

- A. EMEND (fosaprepitant) for injection, for intravenous use. Initial U.S. Approval: 2008
 - a. Single-dose glass vial containing 150 mg of fosaprepitant as a white to off-white lyophilized powder for reconstitution.

CODING

Applicable NDC Codes	
00006-3061-xx *	Emend 150 mg powder for injection, single-dose vial <i>*Available generically from multiple manufacturers</i>

Applicable Procedure Code	
J1453	Injection, fosaprepitant, 1 mg; 1 billable unit = 1 mg

Applicable ICD-10 Codes	
R11.0	Nausea
R11.10	Vomiting, unspecified
R11.11	Vomiting without nausea
R11.12	Projectile vomiting
R11.2	Nausea with vomiting, unspecified
T45.1X5A	Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
T45.1X5S	Adverse effect of antineoplastic and immunosuppressive drugs, sequela
T45.95X5A	Adverse effect of unspecified primarily systemic and hematological agent, initial encounter
T50.905A	Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter
Z51.11	Encounter for antineoplastic chemotherapy
Z51.11	Encounter for antineoplastic immunotherapy

Medical Policy

EVIDENCE BASED REFERENCES

1. Emend [package insert]. Whitehouse Station, NJ; Merck & Co., Inc.; April 2020.
Accessed
March 2022.

POLICY HISTORY

Original Effective Date	5/24/2022
Revised Date	March 1, 2023 - Adopted by MA UM Committee (no policy revisions made)
P&T Committee Endorsement	5/24/2022
Updated to Brand New Day/Central Health Medicare Plan/Central Health Medicare Plan	01/01/2024

Approved by Pharmacy and Therapeutics Committee 5/24/2022